A Study of Flupenthixol Decanoate and Pipotiazine Undecylenate in Schizophrenics

Astrup, Christian; Grimsgård, A.; Hebnes, K.; Kruse-Jensen, A.; Lid, M.

doi:10.1111/j.1600-0447.1974.tb09710.x

Cited by 16 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No hepatotoxicity of flupenthixol decanoate has been described. (Evrard et al 1972, Carney and Sheffield 1973and Astrup et al 1974. A salient fact in our investigation was that 40% of the patients had one or more disturbances in liver function, which was of very low degree in most of the patients.…”

Section: Gielensupporting

confidence: 42%

Disturbances of Liver Function by Long Acting Neuroleptic Drugs

Wa¹,

Borger²

1978

Pharmacopsychiatry

View full text Add to dashboard Cite

In a study in 97 patients on the occurrence of disturbances of liver functions by use of long acting neuroleptic drugs (fluphenazine decanoate, flupenthixol decanoate and fluspirilene) no indications were found that these agents, even in relatively high dosages, are hepatotoxic. Furthermore, in 40% of the patients slight disturbances were found, which nevertheless, were not specific in nature, and mostly concerned the turbidity tests. In spite of these findings a regular control (for instances, once a year) of the liver functions in patients with long acting neuroleptic drugs seems to be called for.

show abstract

Section: Gielensupporting

confidence: 42%

Disturbances of Liver Function by Long Acting Neuroleptic Drugs

Wa¹,

Borger²

1978

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…Controlled studies suggest that some chronic schizophrenics resist ant to neuroleptics at standard doses do indeed respond to high dose regimes (reviewed by Gardos and Cole, 1973). As there had been no double-blind study of high dose flupenthixol, an effective neuroleptic in standard doses when given either orally (Gottfries, 1971) or by the intramuscular route (Astrup et al, 1974), and as it is now possible@to measure plasma levels of flupenthixol accurately, it was decided to investigate this drug in chronic schizophrenics.…”

mentioning

confidence: 99%

High Dose Flupenthixol Decanoate in Chronic Schizophrenia

McCreadie

Flanagan²,

McKnight

et al. 1979

Br J Psychiatry

View full text Add to dashboard Cite

In a double-blind trial, female 'drug-resistant' chronic schizophrenic in-patients were given high dose or standard dose flupenthixol decanoate for 13 weeks. Plasma flupenthixol levels showed a five-fold interindividual variation, but were consistently higher with the high dose. Analysis of final scores showed no statistically significant differences between groups with regards to mental state, ward behaviour and extrapyramidal side-effects. When compared with pre-trial scores, the extrapyramidal side-effects worsened significantly in the high dose patients and social withdrawal decreased in the standard dose patients. The mental state of a sub-group of patients, possibly drug resistant for pharmacokinetic reasons, improved significantly on the high dose over the 13 weeks.

show abstract